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Background: MicroRNA (miRNA) expression is known to be deregulated in ovarian carcinomas. However, limited
data is available about the miRNA expression pattern for the benign or borderline ovarian tumors as well as
differential miRNA expression pattern associated with histological types, grades or clinical stages in ovarian
carcinomas. We defined patterns of microRNA expression in tissues from normal, benign, borderline, and malignant
ovarian tumors and explored the relationship between frequently deregulated miRNAs and clinicopathologic
findings, response to therapy, survival, and association with Her-2/neu status in ovarian carcinomas.
Methods: We measured the expression of nine miRNAs (miR-181d, miR-30a-3p, miR-30c, miR-30d, miR-30e-3p,
miR-368, miR-370, miR-493-5p, miR-532-5p) in 171 formalin-fixed, paraffin-embedded ovarian tissue blocks as well as
six normal human ovarian surface epithelial (HOSE) cell lines using Taqman-based real-time PCR assays. Her-2/neu
overexpression was assessed in ovarian carcinomas (n = 109 cases) by immunohistochemistry analysis.
Results: Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between
carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three
miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues.
Expression of miR-532-5p was significantly lower in borderline than in benign tissues. Among ovarian carcinomas,
expression of four miRNAs (miR-30a-3p, miR-30c, miR-30d, miR-30e-3p) was lowest in mucinous and highest in clear
cell samples. Expression of miR-30a-3p was higher in well-differentiated compared to poorly differentiated tumors
(P= 0.02), and expression of miR-370 was higher in stage I/II compared to stage III/IV samples (P= 0.03). In
multivariate analyses, higher expression of miR-181d, miR-30c, miR-30d, and miR-30e-3p was associated with
significantly better disease-free or overall survival. Finally, lower expression of miR-30c, miR-30d, miR-30e-3p and
miR-532-5p was significantly associated with overexpression of Her-2/neu.
Conclusions: Aberrant expression of miRNAs is common in ovarian tumor suggesting involvement of miRNA in
ovarian tumorigenesis. They are associated with histology, clinical stage, survival and oncogene expression in
ovarian carcinoma.
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Ovarian carcinoma is the most lethal form of gy-
necological malignancy in Korea, with a burden of 4,536
new cases and the highest mortality/incidence (M/I)
ratio (44.8%) among the female genital tract cancers
compared to uterine cervix (26.0%) or corpus (12.8%)
cancers from 2003 to 2005 [1]. The majority of cases are
diagnosed in late stages when metastases are already
present and survival is poor [2]. Current screening
assays, such as serum CA125 and transvaginal ultra-
sound, lack both the sensitivity and specificity needed
for effective early detection of ovarian carcinoma.
Platinum-based chemotherapy is the standard treatment
for patients with advanced ovarian carcinoma, and
current prognostic markers include International Feder-
ation of Gynecology and Obstetrics (FIGO) stages, vol-
ume of residual tumor after cytoreductive surgery,
patient age, histopathological grade, and DNA ploidy [3].
A better understanding of molecular alterations in ovar-
ian carcinoma is necessary to identify novel targets for
early detection and improved treatment.
MicroRNAs (miRNAs) are small noncoding RNAs that
have been implicated in tumor development. They regu-
late target gene expression either by mRNA degradation
or by translation repression [4-11]. Each miRNA may
regulate up to hundreds of target genes [11]. During
tumor development, aberrant expression of miRNAs can
either inactivate tumor suppressor genes or activate onco-
genes, thus promoting tumor formation [4-6,8-10,12]. Be-
cause expression of miRNAs is tissue-specific, detectable
in blood [13], and correlates with clinical cancer behaviors
[14], miRNAs are potential valuable biomarkers.
Numerous studies have identified both upregulated
and downregulated miRNAs in ovarian carcinoma sam-
ples, using both candidate gene [6,13,15] and global profil-
ing [16-25] approaches. Aberrant expression of miRNAs
has also been associated with tumor histology [6,19], re-
sponse to therapy [21,24] and survival [26]. However,
most studies have compared miRNA expression to either
normal ovarian tissues or human ovarian surface epithe-
lial (HOSE) cell lines; it is unknown whether these sam-
ples represent miRNA expression in normal ovarian
epithelial cells [18,27].
We previously identified methylation of three ovarian
carcinoma-specific genes (MINT31, RASSF1, and CDH13)
significantly associated with Her-2/neu overexpression
[28]. Using the TargetScan database (www.targetscan.org)
we identified nine miRNAs that regulate these three genes:
miR-368 targeting MINT31, miR-181d, miR-30a-3p,
miR-30c, miR-30d, miR-30e-3p, miR-370, miR-493-5p
and miR-532-5p targeting CDH13, and miR-181d tar-
geting RASSF1. In the present study, we determined the
expression of these nine miRNAs in benign, borderline
and ovarian carcinoma tissues, as well as HOSE cell linesand normal ovarian tissues by quantitative real-time re-
verse transcription-PCR. In addition, miRNA expression
was correlated with Her-2/neu expression as well as clin-
icopathologic status in ovarian carcinoma.Methods
Clinical ovarian tissue samples
A total of 171 archived formalin-fixed, paraffin-embedded
(FFPE) tissue blocks of normal ovaries (22), and benign
(17), borderline (23) or ovarian carcinoma (109) were
obtained from the pathology department of Bucheon St.
Mary’s Hospital, located in the Gyeongin region of South
Korea, from 1994 to 2004. The patients’ ages ranged from
16 to 88 years, with a median of 52 years. Median ages of
normal, benign, borderline and carcinoma patients were
55 years (range 49 to 68 years), 43 years (range 16 to 88
years), 35 years (range 17 to 72 years), and 52 years (range
20 to 85 years) respectively, with patients with normal
pathology significantly older than women with benign
(P=0.02) or borderline (P= 0.0006) neoplasms, and
women with carcinomas significantly older than women
with borderline (P= 0.0007) neoplasms. None of the study
subjects had a known family history of breast and/or
ovarian cancer, or BRCA1 germ-line mutations. Histo-
logic diagnoses were reviewed by two independent
pathologists. Normal and benign tissues were obtained
from patients who had oophorectomy for benign uterine
pathologies. For carcinoma tissue blocks, only primary
tumor blocks before treatment and those with more than
80% tumor content were used for this study. Detailed
pathological features of benign, borderline, and carcin-
omas are presented in Table 1.
Of the 109 patients with ovarian carcinoma, 41
patients were lost due to transferring to a different hos-
pital, the remaining 68 patients were followed after sur-
gery, both treatment and survival information was
extracted from their medical records. Of these patients,
62 received platinum-based chemotherapy and 32 of
them subsequently received paclitaxel chemotherapy, the
remaining 6 patients did not have any chemotherapy.
Among patients who received chemotherapy, platinum-
sensitive cases were defined as those who had a
progression-free survival of at least six months after the
completion of chemotherapy. Platinum-resistant cases
were defined as patients who progressed through, had
persistent disease at the completion of chemotherapy, or
had recurrent disease within six months after the
chemotherapy. Overall survival was calculated from the
initiation date of primary chemotherapy until the death
or the last follow-up visit (up to 122 months). Disease-
free survival was defined as the interval from the initi-
ation date of primary chemotherapy to the date of
progression.
Table 1 Pathological features of 149 ovarian samples
Tissue diagnosis Number (%)
Benign tumors 17 (11.4)
Serous 7
Mucinous 10










Well-differentiated (grade 1) 19
Moderately differentiated (grade 2) 57






*Histologic grade and International Federation of Gynecology and Obstetrics
(FIGO) stage missing for one ovarian carcinoma case.
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Six normal HOSE cell lines were established from fresh
ovarian scrapings of patients with benign ovarian condi-
tions at the time of surgery and were subsequently
immortalized with HPV16 E6/E7 oncogenes. These cell
lines were cultured in mammary epithelial cell growth
medium (MEGM) (BulletKit, Clonetics; Lonza Group
Ltd, Basel, Switzerland) supplemented with 1% fetal bo-
vine serum, 1% penicillin G sodium and streptomycin
sulfate. Epithelial purity was confirmed by cytokeratin
expression using immunohistochemistry analysis.
RNA extraction
Total RNA from FFPE tissues was extracted using Reco-
verAllTM Total Nucleic Acid Extraction Kit following
the manufacturer’s protocol (Ambion Inc., Austin, TX,
USA). RNA was extracted from HOSE cell lines using
the same kit simply by omitting the deparaffination
steps. RNA concentration and purity was assessed using
UV spectrophotometer.
Reverse transcription and quantitative real-time PCR
(qPCR)
Reverse transcription and quantitative polymerase chain
reactions were performed for the following miRNAs:miR-181d, miR-30a-3p, miR-30c, miR-30d, miR-30e-3p,
miR-368, miR-370, miR-493-5p, and miR-532-5p using
the TaqManTM MicroRNA Reverse Transcription Kit
and the TaqManTM MicroRNA Assays in triplicate (Ap-
plied Biosystems, Foster City, CA, USA). U6 small nu-
clear 2 (RNU6b) was used to normalize input of total
small RNA. Absolute quantification for each miRNA as
well as RNU6b was performed using a standard curve
generated by serial dilution of reverse transcribed total
RNA extracted from VK2 cells, and expression of each
miRNA was presented as the ratio between miRNA and
RNU6b (RQ).
Immunohistochemical analysis of Her-2/neu
overexpression
Archived ovarian carcinoma tissue blocks were used for
immunohistochemistry analysis of Her2/neu overexpres-
sion. Four-micron sections of FFPE tissue were cut and
placed on Superfrost Plus microscope slides (VWR
International, Radnor, PA, USA). The tissue sections
were deparaffinized and rehydrated through graded alco-
hols. Endogenous peroxidase activity was blocked by in-
cubation in 3% H2O2. Antigen retrieval was carried out
with 0.01 M citrate buffer pH 6.0 and microwave heat
induction. Approximately 100 μl of Her2/neu primary
rabbit polyclonal antibody (diluted 1:8,000) (DakoCyto-
mation, Glostrup, Denmark) or antibody diluents lacking
the primary antibody was applied to each slide. The
slides were washed, and biotinylated anti-rabbit antibody
(diluted 1:500) (Vector Laboratories Burlingame, CA,
USA) was applied. After a second wash, the avidin-
biotin-peroxidase complex (Vector Laboratories) was
applied. Color development was accomplished by incu-
bation in diaminobenzidine with 3% H2O2 as a substrate,
and nickel chloride enhancement. The slides were coun-
terstained with methyl green, dehydrated through graded
alcohols, cleared in xylene, and coverslipped with per-
manent mounting media. All cases were reviewed and
scored without knowledge of other laboratory or clinical
results. A case was scored as positive for Her-2/neu over-
expression if it exhibited a staining intensity of 2+ to 3+
with circumscribed membrane staining in more than
10% neoplastic cells, but not in normal cells. A case was
scored as negative for Her-2/neu overexpression if stain-
ing was absent (score 0), staining intensity was 1+ or less,
or if circumscribed membrane staining was absent re-
gardless of staining intensity. Each batch of slides was
run with a known tissue lacking Her-2/neu overexpres-
sion as the negative control and a known tissue with
Her-2/neu overexpression as the positive control, as
well as control breast cancer cell lines with known levels
of Her2/neu expression (MDA-231 (0), MDA-175 (1+)
and SK-BR-3 (3+)) (HercepTest™ Interpretation Manual,
DakoCytomation) [29].
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Expression values of all nine microRNAs were log10
transformed in order to normalize the distribution of
these measurements for all statistical analyses. ANOVA
was used to compare patients’ age across histology and
clinicopathological findings with respect to the RQ of
miRNA expression. In the final analysis, multivariable
adjustments were made to adjust for the potentially con-
founding effects of histological type, stage, grade, and
Her2/neu expression. All P-values were adjusted for
multiple comparisons using false discovery rates. Cox
proportional hazards models were used to assess the
associations between miRNA expression and overall and
disease-free survival. From these models, risk estimates,
expressed as hazard ratios (HR), and 95% confidence
intervals (CI) were calculated. A two-sided 0.05 test level
determined statistical significance for all analyses. All
analyses were conducted using SAS version 9.2 (SAS In-
stitute Inc., Cary, NC, USA).Figure 1 miRNA expression in benign, borderline tumors and ovarian
and ovarian carcinomas was shown by an individual scatter plot. All significInformed consent was obtained according to proce-
dures approved by the Human Subjects Committee of
the Catholic University of Korea and University of
Washington.
Results
MicroRNA expression in clinical samples
We detected significant difference of miRNAs expres-
sion among HOSE cell lines, normal ovaries and benign
ovarian neoplasms (see Additional file 1). Because of the
potential artifacts introduced by in vitro culturing and
transformation in HOSE cell lines and the high content
of stroma cells in normal ovarian tissues, we decided to
use benign ovarian neoplasms as normal control. Ex-
pression of four miRNAs (miR-30c, 30d, 30e-3p, and
370) was significantly different between benign neo-
plasms and ovarian carcinoma: expression of miR-30c
(P=0.02), miR-30d (P=0.001) and miR-30e-3p (P <0.0001)
was higher while expression of miR-370 (P= 0.05) wascarcinomas. Expression of each miRNA in benign, borderline tumors
ant comparisons were labeled (P <0.05).
Lee et al. World Journal of Surgical Oncology 2012, 10:174 Page 5 of 10
http://www.wjso.com/content/10/1/174lower in ovarian carcinomas. In addition, expression of
miR-532-5p (P= 0.01) was lower in borderline than in
benign neoplasms. Finally, we also observed significant
differences in expression between borderline neoplasms
and carcinomas for seven out of nine miRNAs (Figure 1).Association of microRNA expression and histological
types in ovarian carcinomas
Among ovarian carcinoma, we determined whether ex-
pression of specific miRNAs was associated with histo-
logical types (Figure 2). Expression of miR-30a-3p
(P= 0.0002 for serous and P < .0001 for mucinous), miR-
30c (P= 0.01 for serous and P= 0.0006 for mucinous),
and miR-30e-3p (P= 0.006 for serous and P= 0.0005 for
mucinous) were significantly higher in clear cell samples
than in both serous and mucinous samples. Expression
of miR-30d (P= 0.03) was significantly higher in clear
cell samples than in mucinous samples. Lastly, expres-
sion of miR-30c (P= 0.04) and miR-30d (P= 0.04) were
significantly higher in serous carcinomas than in mucin-
ous samples, and expression of miR-30e-3p (P= 0.04)
was significantly higher in clear cell than in endome-
trioid carcinomas.Figure 2 Differential miRNA expression by histological types in ovaria
miR-30d and miR-30e-3p indicated significant differences among differentAssociation of microRNA expression and Her2/neu status,
stage and grade in ovarian carcinomas
In order to assess the independent associations between
miRNA expression and histological type, stage, grade and
Her-2/neu overexpression in ovarian carcinomas, we
conducted multiple ANOVA. Expression of miR-30a-3p
was significantly higher in well-differentiated carcinomas
(grade 1) compared to poorly differentiated carcinomas
(grade 3) (P= 0.02) and expression of miR-181d was mar-
ginally higher in well-differentiated carcinomas (grade 1)
compared to poorly differentiated carcinomas (grade 3)
(P= 0.08). In addition, expression of miR-370 was signifi-
cantly higher in stage I/II carcinomas compared to stage
III/IV (P= 0.03) carcinomas.
Of 109 carcinomas analyzed for Her2/neu overexpres-
sion, 38 (34.9%) were negative for Her2/neu expression,
39 (35.8%) had 1+ staining, 20 carcinomas (18.4%) had 2+
staining, and 12 (11.0%) had 3+ staining. We defined 2+
or 3+ staining cases as positive for Her2/neu expression
in ovarian carcinoma (28). Expression of miR-30c (P=
0.01), miR-30d (P= 0.002), miR-30e-3p (P= 0.008) and
miR-532-5p (P= 0.002) were significantly downregulated
in Her2/neu-positive ovarian carcinomas (Figure 3). In
addition, expressions of miR-181d (P= 0.07), miR-30a-3pn carcinomas. Scatter plots of expression of miR-30a-3p, miR-30c,
histological types.
Figure 3 Correlation of miRNA and Her2/neu expression in ovarian carcinomas. Expression of miR-30c, miR-30d, miR-30e-3p and miR-532-
5p was significantly downregulated among Her2/neu-positive ovarian carcinomas.
Lee et al. World Journal of Surgical Oncology 2012, 10:174 Page 6 of 10
http://www.wjso.com/content/10/1/174(P= 0.12), miR-493-5p (P= 0.06) and miR-368 (P= 0.08)
were downregulated in Her2/neu-positive ovarian carcin-
omas (data not shown).
Association of microRNA expression and platinum
sensitivity, disease recurrence and survival
Although expression of miR-30d was marginally upregu-
lated in ovarian carcinomas which were platinumTable 2 Cox proportional hazards regression analysis of the r
survival
Overall survival (n = 68)
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P va
miR-181d 0.51 (0.19-1.41) 0.20 0.42 (0.14-1.23) 0.11
miR-30a-3p 0.50 (0.20-1.26) 0.14 0.48 (0.19-1.18) 0.11
miR-30c 0.48 (0.13-1.76) 0.27 0.37 (0.10-1.44) 0.15
miR-30d 0.33 (0.11-1.06) 0.06 0.25 (0.07-0.82) 0.02
miR-30e-3p 0.57 (0.20-1.61) 0.29 0.48 (0.17-1.37) 0.17
miR-368 1.60 (0.70-3.68) 0.27 1.79 (0.75-4.25) 0.19
miR-370 1.25 (0.65-2.39) 0.51 1.83 (0.78-4.31) 0.17
miR-493-5p 1.16 (0.47-2.84) 0.75 1.51 (0.57-4.00) 0.41
miR-532-5p 0.89 (0.32-2.52) 0.83 0.84 (0.30-2.36) 0.74
CI, confidence interval; HR, hazard ratio.sensitive (P= 0.054) as opposed to those that were plat-
inum resistant, none of the nine miRNAs were signifi-
cantly associated with platinum sensitivity (data not
shown). Interestingly, miR-30d was also downregulated
in subjects who had recurrent disease (P= 0.15).
We investigated whether there was an association be-
tween miRNA expression overall and disease-free sur-
vival among carcinomas (Table 2). Among the 68elation between miRNAs and overall and disease-free
Disease-free survival (n = 58)
Univariate analysis Multivariate analysis
lue HR (95% CI) P value HR (95% CI) P value
0.60 (0.26-1.41) 0.25 0.34 (0.12-0.94) 0.04
0.56 (0.27-1.16) 0.12 0.46 (0.21-1.00) 0.05
0.44 (0.15-1.30) 0.14 0.27 (0.08-0.92) 0.04
0.41 (0.16-1.08) 0.07 0.33 (0.12-0.90) 0.03
0.48 (0.20-1.18) 0.11 0.39 (0.16-0.94) 0.04
0.84 (0.39-1.78) 0.64 0.92 (0.43-1.97) 0.84
1.23 (0.74-2.06) 0.43 1.77 (0.93-3.34) 0.08
1.27 (0.58-2.77) 0.55 1.70 (0.74-3.94) 0.21
0.84 (0.34-2.07) 0.70 0.69 (0.27-1.74) 0.43
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died during follow-up and their median survival time
was 72 months. There were 58 women available for
disease-free survival analysis, 30 of them recurred during
follow-up and their median disease-free survival time was
32 months. All miRNAs except for three (miR-368, miR-
370, and miR-493-5p) had hazard ratios less than one for
every one unit increase in log10 miRNA expression for
both overall and disease-free survival. In univariate mod-
els investigating overall survival, there was a moderate
decreased risk of death associated with increased expres-
sion of miR-30d (P=0.06). This association achieved sig-
nificance after adjusting for age and stage (P=0.02). In a
univariate model investigating disease-free survival, there
was a moderate decreased risk of recurrence for miR-
181d (P=0.25), miR-30c (P=0.14), miR-30d (P=0.07),
and miR-30e-3p (P=0.11). These associations became sig-
nificantly associated with a decreased risk of recurrence
after adjusting for age and stage.
Discussion
In the present study, we identified that expression of four
miRNAs was significantly different between ovarian car-
cinomas and benign neoplasms, and differential miRNA
expression was associated with histological types, grade
and stage, as well as both disease-free survival and overall
survival. Finally, miRNA expression was associated with
Her2/neu oncogene expression. To the best of our know-
ledge, this is the first study that miRNA expression in
ovarian carcinomas was compared to benign neoplasms
by the quantitative real-time PCR method.
This study is the first to examine the relationship be-
tween miRNA alterations and Her-2/neu expressions in
ovarian carcinomas. Several studies have identified spe-
cific miRNAs associated with Her2/neu expression in
breast cancers. Using stepwise artificial neural networks
(ANN) analysis, Lowery et al. identified a predictive
miRNA signature (miR-520d, miR-181c, miR-302c, miR-
376b, miR-30e) corresponding with Her2/neureceptor
status [30]. Huang et al. [31] showed that miR-21 is up-
regulated in Her2/neu-positive breast cancer cells via the
MAPK (ERK1/2) pathway. The expression of miR-221 and
miR-222 was significantly elevated in Her2/neu-positive
primary human breast cancer tissues when compared
with Her2/neu-negative tissue samples [32].
We previously identified that methylation of three
genes (MINT31, RASSF1, and CDH13) was significantly
associated with Her2/neu overexpression in ovarian car-
cinoma from the United States [28]. In this study, we
determined whether expression of miRNAs targeting
these three genes was also associated with Her2/neu
overexpression. Based on findings using the TargetScan
software, miR-368 targets MINT31, miR-181d, 30a-3p,
30c, 30d, 30e-3p, 370, 493-5p, and 532-5p target CDH13,and miR-181d targets RASSF1. Interestingly, expression
of miR-30c, 30d, 30e-3p and 532-5p were significantly
higher in Her-2/neu-negative than in Her-2/neu-positive
ovarian carcinoma. Based on our data, we hypothesize
that CDH13 can be downregulated in ovarian carcinoma
by two different pathways: in Her2/neu-negative ovarian
carcinoma, CDH13-targeting miRNAs are sufficient to in-
activate CDH13; in Her2/neu-positive ovarian carcinoma,
these miRNAs are downregulated, CDH13 was inacti-
vated through promoter DNA methylation. The high per-
centage of Her2/neu-positive ovarian carcinomas (29.4%)
in the present study is likely due to the inclusion of 39%
non-serous carcinomas (mucinous, endometrioid and
clear cell types). The percentage of Her2/neu-positive ser-
ous carcinomas and non-serous carcinomas was 22.7%
and 39.5% respectively in our study, which is consistent
with what has been reported [33].
Our data on miRNA expression in ovarian carcinomas
are consistent with what have been reported in the lit-
erature [6,19,26]. Wyman et al. showed that miR-30c,
miR-30d and miR-30e were upregulated, while miR-493
was downregulated in ovarian carcinomas when com-
pared to normal HOSE cell lines, and expression of
miR-30a was specific to the clear cell histological type
[19]. Zhang et al. reported downregulation of miR-368
and 370 in ovarian carcinomas [6]. Laios et al. showed
significant downregulation of miR-30d in patients with
recurrent ovarian carcinomas [26]. However, our study
is unique in that we compared miRNA expression in
ovarian carcinoma to benign or borderline tumor,
whereas previous studies used HOSE cell lines or normal
ovaries as controls. We identified that expression of four
miRNAs (miR-30c, 30d, 30e-3p, and 370) was signifi-
cantly different between ovarian carcinoma and benign
tumor. Furthermore, expression of one miRNA was dif-
ferent between benign and borderline tumor and expres-
sion of seven miRNAs was different between borderline
tumor and carcinoma. From our results, we hypothesize
that these miRNAs are involved in ovarian tumorigen-
esis, especially at the stage of progression from border-
line tumor to carcinoma. We identified that several
miRNAs (miR-30a-3p, miR-30c, miR-30d, and miR-30e-
3p) differently expressed in ovarian carcinoma with dif-
ferent histological types and this finding is pertinent to
the fact that different histological types are biologically
and pathogenetically distinct entities [16]. Although we
did not detect downregulation of miR-368 in poorly dif-
ferentiated carcinoma, which had been previously
reported [6], we identified that high expression levels of
miR-30a-3p and 370 were associated with well-
differentiated tumor grade and early clinical stage in
ovarian carcinoma, respectively.
Several studies reported association of expression of
miR-30c and 370 with response to chemotherapy in
Lee et al. World Journal of Surgical Oncology 2012, 10:174 Page 8 of 10
http://www.wjso.com/content/10/1/174ovarian carcinoma [21,24]. However, we did not detect
any significant association between miRNA expression
and platinum sensitivity in our study, although miR-30d
were marginally upregulated in subjects who were plat-
inum sensitive. The miRNA expression discrepancy we
observed might be due to differences in type of speci-
mens (cell lines versus tumor tissue), the inclusion of
different histological subtypes, heterogeneity of the
tumor, and RNA isolation protocols and detection plat-
forms [27]. For example, more than 40% (44/108) of our
carcinoma samples was early stage (I/II) and 39% of the
early stage cases (17/44) were mucinous histology.
We showed that expression of miR-30d was signifi-
cantly associated with both overall survival and disease-
free survival in the multivariate analysis. In addition,
miR-181d, miR-30c and miR-30e-3p were also signifi-
cantly associated with disease-free survival in the multi-
variate analysis. Several studies have investigated the role
of miRNA expression as prognostic markers in ovarian
carcinoma [20,21,27,34,35]. Hu et al. showed that high
expression of miR-200a was associated with recurrence-
free survival and overall survival in ovarian carcinoma
using multivariate Cox proportional analysis [36]. Les-
kelä et al. showed that high expression of miR-429 was
associated with both recurrence-free survival and overall
survival in ovarian carcinomas [37]. Wurz et al. showed
that a higher ratio of miR-221/222 was associated with
better overall survival [38]. A recent study in stage I
ovarian carcinomas indicated that high expression of
miR-200c was associated with better progression-free
and overall survival [39].
Expression of miR-30c, 30d and 30e-3p has also been
associated with survival in other types of cancer. For ex-
ample, downregulation of expression of miR-30c has been
associated with shorter progression-free survival in clear
cell renal carcinoma [40] and breast cancer [41], but bet-
ter survival in malignant mesothelioma [42], and low
plasma level of miR-30e-3p was associated with shorter
disease-free survival in non-small cell lung cancer [43].
However, upregulation of miR-30d was correlated with
shorter time to recurrence and reduced overall survival in
melanoma [44] and non-small cell lung cancer [45].
We detected significant differences among HOSE cell
lines, normal ovarian tissues and benign neoplasms (sup-
plemental data), this is consistent with what we had pre-
viously reported for DNA methylation analysis [28].
Since most of existing miRNA analysis studies used ei-
ther HOSE cell lines or normal ovaries as normal con-
trols, the reported results and conclusions should be
interpreted with caution.
Conclusions
We identified several miRNAs being aberrantly expressed
in ovarian carcinomas when compared to benign orborderline ovarian tumors, suggesting that these miRNAs
are involved in ovarian tumorigenesis. In addition, expres-
sion of some miRNAs was associated with distinct histo-
logical type while expression of others was associated
with grade and clinical stage. Finally, expression of some
miRNAs was associated with survival and oncogene ex-
pression in ovarian carcinomas. Future studies are needed
to validate our findings and further elucidate the mechan-
ism of miRNA expression regulation during ovarian
tumorigenesis.
Additional file
Additional file 1: miRNA expression in HOSE cell lines, normal
ovaries, and benign ovarian tumors. Expression of miR-181d, miR-368,
and miR-370 was significantly different between cell lines and normal
ovaries as well as between cell lines and benign tumors. In addition,
expression of miR-30c and miR-30e-3p was significantly different
between cell lines and normal ovaries, and expression of miR-30c was
significantly different between normal ovaries and benign tumors.
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